Clinical Trial Update: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MEDI0457 with Durvalumab in HPV-positive recurrent/metastatic head and neck cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• MEDI0457

Snippet

Sponsor: MedImmune LLC | Conditions: Head and Neck Cancer, Human Papilloma Virus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-25